Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 639450, 11 pages
http://dx.doi.org/10.1155/2015/639450
Research Article

Effects of Qili Qiangxin Capsule on AQP2, V2R, and AT1R in Rats with Chronic Heart Failure

1Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
2Beijing University of Chinese Medicine, Beijing 100029, China
3Institute of Basic Theory, China Academy of Traditional Chinese Medicine, Beijing 100700, China
4The Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China

Received 2 April 2014; Revised 21 July 2014; Accepted 11 August 2014

Academic Editor: Hao Xu

Copyright © 2015 Xiangning Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Berry, D. R. Murdoch, and J. J. V. McMurray, “Economics of chronic heart failure,” European Journal of Heart Failure, vol. 3, no. 3, pp. 283–291, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Chen, S. L. Normand, Y. Wang, and H. M. Krumholz, “National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008,” The Journal of the American Medical Association, vol. 306, no. 15, pp. 1669–1678, 2011. View at Google Scholar
  3. J. J. V. Mcmurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC,” European Journal of Heart Failure, vol. 14, no. 8, pp. 803–869, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics—2013 update: a report from the American Heart Association,” Circulation, vol. 127, no. 1, pp. e6–e245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. P. Morrissey, L. Czer, and P. K. Shah, “Chronic heart failure: current evidence, challenges to therapy, and future directions,” The American Journal of Cardiovascular Drugs, vol. 11, no. 3, pp. 153–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Shchekochikhin, F. Al Ammary, J. Lindenfeld, and R. Schrier, “Role of diuretics and ultrafiltration in congestive heart failure,” Pharmaceuticals, vol. 6, no. 7, pp. 851–866, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Nielsen, J. Terris, D. Andersen et al., “Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 5450–5455, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. S. C. Lütken, S. W. Kim, T. Jonassen et al., “Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade,” The American Journal of Physiology—Renal Physiology, vol. 297, no. 6, pp. F1678–F1688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Wang, C. Li, S. Summer, S. Falk, and R. W. Schrier, “Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration,” American Journal of Physiology: Renal Physiology, vol. 299, no. 3, pp. F577–F584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. W. Schrier, “Interactions between angiotensin II and arginine vasopressin in water homeostasis,” Kidney International, vol. 76, no. 2, pp. 137–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. T.-H. Kwon, J. Nielsen, M. A. Knepper, J. Frøkiær, and S. Nielsen, “Angiotensin II AT1 receptor blockade decreases vasopressin-induced water reabsorption and AQP2 levels in NaCl-restricted rats,” American Journal of Physiology—Renal Physiology, vol. 288, no. 4, pp. F673–F684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Li, J. Zhang, J. Huang et al., “A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure,” Journal of American College of Cardiology, vol. 62, no. 12, pp. 1065–1072, 2013. View at Google Scholar
  13. H. Xiao, Y. Song, Y. Li, Y. H. Liao, and J. Chen, “Qiliqiangxin regulates the balance between tumor necrosis factor-α and interleukin-10 and improves cardiac function in rats with myocardial infarction,” Cellular Immunology, vol. 260, no. 1, pp. 51–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Liu, J. Chen, T. Xu et al., “Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase,” American Journal of Hypertension, vol. 25, no. 2, pp. 250–260, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Zou, L. Lin, Y. Ye et al., “Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice,” Journal of Cardiovascular Pharmacology, vol. 59, no. 3, pp. 268–280, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Wei, X. Liu, L. Hou, W. Che, E. The, and M. V. Jhummon, “Qiliqiangxin affects L type Ca2+ current in the normal and hypertrophied rat heart,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 131830, 4 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. D. Wei, X. Y. Liu, H. D. Wei et al., “The electrophysiological effects of qiliqiangxin on cardiac ventricular myocytes of rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 213976, 4 pages, 2013. View at Publisher · View at Google Scholar
  18. J. F. Zhang, C. Wei, H. T. Wang et al., “Protective effect of qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 378298, 9 pages, 2013. View at Publisher · View at Google Scholar
  19. D. Liang and M. Zhang, “The thinking on TCM differential treatment of congestive heart failure,” Journal of Traditional Chinese Medicine, vol. 20, no. 1, pp. 44–47, 2000. View at Google Scholar · View at Scopus
  20. Y. Noda, “Dynamic regulation and dysregulation of the water channel aquaporin-2: a common cause of and promising therapeutic target for water balance disorders,” Clinical and Experimental Nephrology, vol. 18, no. 4, pp. 558–570, 2013. View at Google Scholar
  21. T. Imamura, K. Kinugawa, T. Fujino et al., “Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure,” Circulation Journal, vol. 78, no. 9, pp. 2240–2249, 2014. View at Google Scholar
  22. S. R. Goldsmith, G. S. Francis, A. W. Cowley Jr., T. B. Levine, and J. N. Cohn, “Increased plasma arginine vasopressin levels in patients with congestive heart failure,” Journal of the American College of Cardiology, vol. 1, no. 6, pp. 1385–1390, 1983. View at Publisher · View at Google Scholar · View at Scopus
  23. N. L. Wong and J. K. Tsui, “Upregulation of vasopressin V2 and aquaporin 2 in the inner medullary collecting duct of cardiomyopathic hamsters is attenuated by enalapril treatment,” Metabolism, vol. 51, no. 8, pp. 970–975, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Nielsen, J. Frøkiær, D. Marples, T.-H. Kwon, P. Agre, and M. A. Knepper, “Aquaporins in the kidney: from molecules to medicine,” Physiological Reviews, vol. 82, no. 1, pp. 205–244, 2002. View at Google Scholar · View at Scopus
  25. S. Nielsen, C.-L. Chou, D. Marples, E. I. Christensen, B. K. Kishore, and M. A. Knepper, “Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 4, pp. 1013–1017, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Katsura, C. E. Gustafson, D. A. Ausiello, and D. Brown, “Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells,” The American Journal of Physiology, vol. 272, no. 6, part 2, pp. 817–822, 1997. View at Google Scholar · View at Scopus
  27. B. W. M. van Balkom, P. J. M. Savelkoul, D. Markovich et al., “The role of putative phosphorylation sites in the targeting and shuttling of the aquaporin-2 water channel,” The Journal of Biological Chemistry, vol. 277, no. 44, pp. 41473–41479, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Gheorghiade, M. A. Konstam, J. C. Burnett Jr. et al., “Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials,” Journal of the American Medical Association, vol. 297, no. 12, pp. 1332–1343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Konstam, M. Gheorghiade, J. C. Burnett et al., “Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST out come trial,” The Journal of the American Medical Association, vol. 297, no. 12, pp. 1319–1331, 2007. View at Google Scholar
  30. N. L. M. Wong and J. K. C. Tsui, “Angiotensin II upregulates the expression of vasopressin V2 mRNA in the inner medullary collecting duct of the rat,” Metabolism: Clinical and Experimental, vol. 52, no. 3, pp. 290–295, 2003. View at Publisher · View at Google Scholar · View at Scopus